SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:oru-76981"
 

Search: id:"swepub:oai:DiVA.org:oru-76981" > Effect of adding da...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Lahtela, J.TAYS, Tampere, Finland (author)

Effect of adding dapagliflozin as an adjunct to insulin on urinary albumin-to-creatinine ratio over 52 weeks in adults with type 1 diabetes

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • Springer,2019
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-76981
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-76981URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:vet swepub-contenttype
  • Subject category:kon swepub-publicationtype

Notes

  • Background and aims: Dapagliflozin (DAPA), as an adjunct to insulin, was reported to improve glycaemic control, reduce body weight, and was well tolerated (DEPICT-1 and 2 studies) in adults with inadequately controlled type 1 diabetes (T1D; HbA1c: 58-91 mmol/mol [7.5-10.5%]).Materials and methods: In this pooled post hoc analysis of the DEPICT-1 and -2 studies, the effect of DAPA on urinary albumin-to-creatinine ratio (UACR) was evaluated in individuals with T1D with baseline micro or macroalbuminuria.Results: UACR was recorded at baseline for 548, 565, and 532 individuals treated with DAPA 5 mg, DAPA 10 mg, and placebo, respectively; baseline albuminuria was found in 80, 84, and 87 of these individuals in the respective arms. Of these 251 individuals, baseline renal function measured as estimated glomerular filtration rate (eGFR) was normal (eGFR≥90 ml min-1[1.73 m]-2) in 93, mildly impaired in (eGFR≥60-<90 ml min-1[1.73 m]-2) 131, and moderately impaired in 27 individuals (eGFR <60 ml min-1[1.73 m]-2). Changes in eGFR were similar across the treatment arms (data not shown). Dose-dependent decrease in UACR was observed with DAPA treatment at Weeks 12, 18, 24, and 52 (Figure). At Week 52, the differences in UACR between DAPA 10 mg vs placebo and DAPA 5 mg vs placebo were−31.1% (95% CI:−49.9,−5.2) and−13.3 (95% CI:−37.2, 19.8), respectively.Conclusion: Treatment with DAPA, as an adjunct to insulin, provided a dose-dependent benefit in reducing UACR, suggesting renoprotective effects in individuals with T1D with baseline albuminuria.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Edelman, S.Division of Endocrinology and Metabolism, University of California, San Diego, USA (author)
  • Jendle, Johan,1963-Örebro universitet,Institutionen för medicinska vetenskaper(Swepub:oru)jje (author)
  • Dandona, P.Division of Endocrinology, Metabolism and Diabetes, State University of New York at Buffalo, Buffalo, USA (author)
  • Mathieu, C.University of Leuven, Leuven, Belgium (author)
  • Thorén, F.AstraZeneca, Gothenburg, Swede (author)
  • Scheerer, M.F.AstraZeneca, Wedel, Germany (author)
  • Xu, J.AstraZeneca, Gaithersburg, USA (author)
  • Langkilde, A.M.AstraZeneca, Gothenburg, Swede (author)
  • TAYS, Tampere, FinlandDivision of Endocrinology and Metabolism, University of California, San Diego, USA (creator_code:org_t)

Internet link

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view